Revance Therapeutics, Inc.
Revance Therapeutics, Inc. (RVNC): 122 pipeline candidates · ~17 mo cash runway · 157 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
16.5 months
D/E -3.83 · 0% dilution
Lead: Phase 2
122 candidates
N/A
N/A
A transparent, data-derived signal for Revance Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$64.6M
Quarterly Burn
$41.1M
Runway
16.5 mo
Revenue
$59.9M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (122 candidates)
| Drug | Phase |
|---|---|
| 1% lidocaine with sodium bicarbonate | Phase 4 |
| 10U/0,1 ml Botulinum toxin A | Phase 4 |
| 25 units botox | Phase 4 |
| 50 units Botox | Phase 4 |
| 5U/0,1 ml Botulinum toxin A | Phase 4 |
| 75 units Botox | Phase 4 |
| AboBoNT-A | Phase 4 |
| Abobotulinumtoxin A | Phase 4 |
| AbobotulinumtoxinA | Phase 4 |
| Amifampridine | Phase 2 |
Showing 10 of 122 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in Revance Therapeutics, Inc.'s pipeline?
Revance Therapeutics, Inc. (RVNC) has 122 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Revance Therapeutics, Inc.'s lead drug candidate?
Revance Therapeutics, Inc.'s most advanced tracked candidate is 1% lidocaine with sodium bicarbonate (Phase 4) for Urinary Incontinence.
What is Revance Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Revance Therapeutics, Inc. has approximately 16.5 months of cash runway.
Get the full picture on Revance Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.